Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H16N6O2 |
| Molecular Weight | 240.2623 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](O)[C@H](O)[C@H]1CNC2=NC(N)=NC(N)=C2N1
InChI
InChIKey=NDSDGUULXHNXGA-RPDRRWSUSA-N
InChI=1S/C9H16N6O2/c1-3(16)6(17)4-2-12-8-5(13-4)7(10)14-9(11)15-8/h3-4,6,13,16-17H,2H2,1H3,(H5,10,11,12,14,15)/t3-,4+,6-/m0/s1
| Molecular Formula | C9H16N6O2 |
| Molecular Weight | 240.2623 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Vasopharm BIOTECH is developing 4-aminotetrahydrobiopterin (ronopterin, VAS 203), a nitric oxide synthase inhibitor, for the treatment of traumatic brain injury. Ronopterin is an allosteric nitric oxide (NO) synthase inhibitor interacting with the tetrahydrobiopterinbinding site of the enzyme. Pre-clinical, proof-of-principle studies using controlled cortical impact showed that VAS203 had significant and positive effects on elevated intracranial pressure (ICP), which contributes to the deleterious consequences of TBI, as well as on neurological outcome measured with behavioural tests. By targeting both cerebral blood vessels and cerebral tissue in a region-specific manner VAS203 represents a completely novel pharmacological approach to TBI that can be administrated in addition to best standard of care. Ronopterin is currently in development for the treatment of traumatic brain injury.In the phase III clinical trial, ronopterin is administered as a 17 mg/kg intravenous infusion over 48 hours (daily dose of 8.5 mg/kg).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19514849
Curator's Comment: VAS-203 passed the BBB both in healthy and traumatized mouse brain
Originator
Approval Year
Sample Use Guides
In the phase III clinical trial, ronopterin is administered as a 17 mg/kg intravenous infusion over 48 hours (daily dose of 8.5 mg/kg)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11139456
Endothelium-dependent relaxations of pig pulmonary and coronary artery strips to bradykinin or calcium ionophore A23187 were inhibited by 4-aminotetrahydrobiopterin in a concentration-dependent manner. Half-maximal inhibition was observed at 60 - 65 uM (pulmonary artery) and 200 - 250 uM 4-aminotetrahydrobiopterin (coronary artery). Pig coronary artery strips precontracted with 0.1 uM 9, 11-dideoxy-9, 11-methanoepoxy-prosta-glandin F(2alpha) (U46619) showed a time-dependent relaxation (monitored for up to 18 h) upon incubation with 1 ug ml(-1) lipopolysaccharide (LPS). Addition of 10 uM 4-aminotetrahydrobiopterin 1 h after LPS led to a pronounced inhibition of the LPS-triggered relaxation. Incubation of pulmonary and coronary artery strips with 1 ug ml(-1) LPS attenuated contractile responses to norepinephrine (1 uM) and U46619 (0.1 uM). This hyporeactivity of the blood vessels to vasoconstrictor agents was inhibited by 4-aminotetrahydrobiopterin in a concentration-dependent manner [IC(50)=17.5+/-5.9 uM (pulmonary artery) and 20.7+/-3 uM (coronary artery)]. The effect of 0.1 mM 4-ABH(4) was antagonized by coincubation with 0.1 mM sepiapterin.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:13:30 GMT 2025
by
admin
on
Mon Mar 31 23:13:30 GMT 2025
|
| Record UNII |
1D1Z87AY23
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29574
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5287516
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
PRIMARY | |||
|
100000171835
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
PRIMARY | |||
|
185243-78-1
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
PRIMARY | |||
|
C152249
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
PRIMARY | |||
|
1D1Z87AY23
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
PRIMARY | |||
|
9881244
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
206885-38-3
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
DB12575
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
PRIMARY | |||
|
10122
Created by
admin on Mon Mar 31 23:13:30 GMT 2025 , Edited by admin on Mon Mar 31 23:13:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|